← Leaderboards
Gyanu Lamichhane
Johns Hopkins University
$9,492,958
Attributed
$9,492,958
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,492,958 · 12
By mechanism
R21$2,675,375 · 6
DP2$2,630,000 · 1
R01$2,092,054 · 1
R33$1,448,698 · 1
R56$410,000 · 1
R03$236,831 · 2
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Craig A Townsend$23,597,395
- Eric L Nuermberger$20,859,483
- Jacques H. Grosset$1,997,313
- Daniel Lyndon Jaffe Thorek$4,988,087
Others in their field
Top investigators on “Antibiotics”
- Laurence H Baker · University Of Michigan At Ann Arbor$52,071,546
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,812,829
- Taha E Taha · Johns Hopkins University$37,363,329
- Urs Ochsner · Crestone, Inc.$36,950,837
- Deborah T Hung · Massachusetts General Hospital$36,871,538
- Ryan Cirz · Revagenix, Inc.$35,410,554
Research focus
AntibioticsInfectionPharmaceutical PreparationsResistanceMycobacterium TuberculosisChronicGrowthBacteriaStructureMouse ModelIn VitroPeptidyltransferaseDrug ResistanceBaseBacterial InfectionsResistant StrainInhibitor/AntagonistEnzymesRegimenDoseExhibitsIncidenceLungMycobacterium Abscessus
Grant awards (24)
A less resource-intensive mouse model of M. abscessus lung disease$426,938
R21 · FY2025 · AI · contact PI
An unconventional regimen comprising biofilm disruptor as an adjunct with antibiotics to treat Mycobacterium abscessus chronic lung disease$155,227
R03 · FY2025 · AI · contact PI
A strategy for new regimens to treat pulmonary Mycobacteroides abscessus infection$409,375
R01 · FY2024 · AI · contact PI
A strategy for new regimens to treat pulmonary Mycobacteroides abscessus infection$409,375
R01 · FY2023 · AI · contact PI
A strategy for new regimens to treat pulmonary Mycobacteroides abscessus infection$458,677
R01 · FY2022 · AI · contact PI
Reference strains of Mycobacteroides abscessus$239,698
R21 · FY2022 · AI · contact PI
A strategy for new regimens to treat pulmonary Mycobacteroides abscessus infection$401,896
R01 · FY2021 · AI · contact PI
Oral dual β-lactams to treat pulmonary M. abscessus disease$245,625
R21 · FY2021 · AI · contact PI
Reference strains of Mycobacteroides abscessus$209,151
R21 · FY2021 · AI · contact PI
A strategy for new regimens to treat pulmonary Mycobacteroides abscessus infection$412,731
R01 · FY2020 · AI · contact PI
A strategy to treat M. abscessus infections$245,625
R21 · FY2020 · AI · contact PI
Oral dual β-lactams to treat pulmonary M. abscessus disease$204,688
R21 · FY2020 · AI · contact PI
A strategy to treat M. abscessus infections$204,688
R21 · FY2019 · AI · contact PI
Development of an Oral Carbapenem Drug for Treatment of Drug Resistant TB$471,845
R33 · FY2018 · AI · contact PI
Development of an Oral Carbapenem Drug for Treatment of Drug Resistant TB$478,053
R33 · FY2017 · AI · contact PI
Towards a new regimen to treat mycobacterial infection in cystic fibrosis patients$243,000
R21 · FY2017 · AI · contact PI
Mutations that Confer Mycobacteria Resistance to Carbapenems$81,604
R03 · FY2017 · AI · contact PI
Development of an Oral Carbapenem Drug for Treatment of Drug Resistant TB$498,800
R33 · FY2016 · AI · contact PI
Towards a new regimen to treat mycobacterial infection in cystic fibrosis patients$202,500
R21 · FY2016 · AI · contact PI
Development of an Oral Carbapenem Drug for Treatment of Drug Resistant TB$217,406
R21 · FY2015 · AI · contact PI
Development of an Oral Carbapenem Drug for Treatment of Drug Resistant TB$236,056
R21 · FY2014 · AI · contact PI
New Drug for Treatment of Chronic Bacterial Infection$200,000
DP2 · FY2013 · OD · contact PI
New Drug for Treatment of Chronic Bacterial Infection$2,430,000
DP2 · FY2011 · OD · contact PI
NOVEL LINKAGES OF THE PEPTIDOGLYCAN LAYER: ADAPTATION & RESISTANCE TO B-LACTAMS$410,000
R56 · FY2011 · AI · contact PI